FDA clears first new hep B vaccine in 25 years
The US Food and Drug Administration is allowing onto the market the first new hepatitis B vaccine in more than 25 years with the approval of Dynavax’ Heplisav-B.
Read More
Tag: Dynavax
Vectura allows Dynavax access to smart inhalers
Vectura has signed an exclusive global agreement with Dynavax Technologies allowing use of its proprietary smart nebuliser technology to deliver an investigational immunotherapeutic to lung cancer patients.
Read More
FDA rejects Dynavax’ hepatitis B vaccine
Shares in US group Dynavax Technologies fell through the floor after US regulators refused to approve its flagship hepatitis B vaccine Heplisav-B.
Read More
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
